1. Incyte Reports Updated Results of Pemigatinib in P-II FIGHT-202 Trial for Patients with Previously Treated Advanced Cholangiocarcinoma Published: Sept 27, 2019 | Tags: Incyte, Reports, Updated, Results, Pemigatinib, P-II, FIGHT-202 […]readmore
Tags : Clovis Oncology
Shots: 3BP to receive $12M up front, R&D milestones, an additional potential milestone with royalties on sales. Clovis to get rights to develop peptide-targeted radionuclide therapy (PTRT) and imaging agent […]readmore
Shots: The P-III ARIEL3 study results involves assessing of Rubraca (rucaparib, 600mg, bid) vs PBO in 564 patients in a ratio (2:1) with platinum-sensitive recurrent ovarian cancer including patients with […]readmore
Shots: Clovis Oncology’s Rubraca (rucaparib) enters in EU with its first launch in Germany and is approved for both treatment and maintenance treatment of ovarian cancer in women The launch […]readmore
Shots: The companies enter into an agreement to jointly evaluate safety & efficacy of Alkermes’ ALKS 4230 in combination with Clovis Oncology’s Rucaparib & Lucitanib with equal cost sharing in […]readmore
Shots: The approval is based on P-III ARIEL3 study results assessing Rubraca (600mg, bid) vs PBO in 564 women in a ratio (2:1) with a recurrent epithelial ovarian, fallopian tube or primary […]readmore